title: Paecilomyces lilacinus scleritis with secondary keratitis.
abstract: OBJECTIVE
  To report a case of Paecilomyces lilacinus scleritis with secondary keratitis after initially diagnosed immune-based scleritis.
  
  
  METHODS
  An 82-year-old man was diagnosed with immune-based scleritis and treated with oral cyclophosphamide 50 mg twice daily. However, multiple scleral abscesses and a fibrinoid aqueous reaction developed 3 months later. Infectious scleritis was suspected. The culture from the necrotic sclera grew P. lilacinus. Despite treatment with antimicrobials, the infection progressed to the cornea. The medication included topical natamycin suspension 5% and fluconazole 2 mg/mL hourly, as well as oral itraconazole 100 mg daily. Debridement of the necrotic tissue and intracameral injection with amphotericin-B were performed.
  
  
  RESULTS
  The infection resolved 4 months later, although its resolution was accompanied by development of phthisis bulbi, and the visual acuity remained light perception.
  
  
  CONCLUSIONS
  Infection by P. lilacinus can occur in a patient with scleritis. Infectious scleritis is a particular risk in cases involving diabetes mellitus, prior scleritis, previous surgery, and immunosuppression. Early detection of the microorganism and aggressive treatment are necessary to eradicate such an infection; however, the prognosis for vision recovery can remain poor despite treatment.
authors.affiliation: Department of Ophthalmology, Chang Gung Memorial Hospital, and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
authors.forename: Pei-Chen
authors.initials: PC
authors.lastname: Chung
authors.forename: Hsin-Chiung
authors.initials: HC
authors.lastname: Lin
authors.forename: Yih-Shiou
authors.initials: YS
authors.lastname: Hwang
authors.forename: Yueh-Ju
authors.initials: YJ
authors.lastname: Tsai
authors.forename: Kah-Wai
authors.initials: KW
authors.lastname: Ngan
authors.forename: Samuel C M
authors.initials: SC
authors.lastname: Huang
authors.forename: Ching-Hsi
authors.initials: CH
authors.lastname: Hsiao
mesh_terms: D000284:Administration, Oral; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage; D003646:Debridement; D004359:Drug Therapy, Combination; D015821:Eye Infections, Fungal / Q000150:complications* / Q000382:microbiology / Q000628:therapy; D015725:Fluconazole / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage; D007634:Keratitis / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D008297:Male; D010866:Natamycin / Q000008:administration & dosage; D009883:Ophthalmic Solutions; D010143:Paecilomyces / Q000302:isolation & purification*; D012590:Sclera / Q000382:microbiology* / Q000473:pathology; D015423:Scleritis / Q000150:complications* / Q000382:microbiology / Q000628:therapy
chemical_list: D000935:Antifungal Agents; D009883:Ophthalmic Solutions; D017964:Itraconazole; D010866:Natamycin; D015725:Fluconazole